PRESS RELEASE
- Remote monitoring technology enables timely intervention and improves patient outcomes
KUALA LUMPUR, 13 June 2023 – Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) has signed a Memorandum of Understanding (MoU) with Singapore-based digital therapeutics company Respiree Pte Ltd. (“Respiree”) to collaborate in introducing digitization of case management and remote monitoring for patients with chronic obstructive pulmonary disease (COPD), asthma and sleep apnea, and other respiratory conditions in Malaysia.
“In line with our mission of being the “Leading Healthcare Group Providing Quality and Innovative Solutions”, and our vision of “Providing Smarter Solutions for a Healthier Life” we are always on the lookout for collaborations that can offer intelligent healthcare solutions that improve lives. In the case of COPD patients in Malaysia, the readmission rate into government hospitals is relatively high, and given the congestion in wards, remote monitoring can have a significant positive impact in reducing the need for readmission,” said Wan Amir-Jeffery Bin Wan Abdul Majid, Chief Executive Officer-Commercial of Duopharma Biotech Berhad.
“Real time monitoring enables medical personnel to detect changes in patient health, thus also enabling timely intervention and improving patient outcomes. In addition, remote monitoring also helps patients living in remote areas or those who face challenges in travelling to healthcare facilities for regular check-ups,” he added.
Dr Gurpreet Singh, Founder and CEO of Respiree Pte Ltd. commented, “COPD exacerbations drive both morbidity and mortality. It is important hence to be able to identify them early and intervene with the right therapeutic. By using Respiree’s RS001, physicians can now have the opportunity to identify exacerbations, not hours or minutes in advance, but days in advance, using respiratory physiologic data. This can enable patients to quickly receive preventive care promptly before exacerbation onset”.